You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers reported shared and distinct genetic contributors to systemic lupus erythematosus in individuals with African or European ancestry.
The researchers found differences in mutational patterns among their African-American patients and that liquid biopsies seem to catch metastases early.
An international team of researchers also suggested that MUC16 mutations could identify patients who might benefit from immunotherapy treatment.
Wake Forest researchers are in the midst of an ongoing precision oncology trial to see how NGS-based tumor profiling and liquid biopsy assays can be implemented.
The organizations in the consortium will identify, characterize, and catalog human biological molecules affected by physical activity in volunteer biosamples.
The researchers said the technique could be used to identify biomarkers specific to cancer or bacterial infection that are too small to detect by other methods.
This article was originally published May 23.
NEW YORK (GenomeWeb News) – Wake Forest University and spin-out company NanoMedica have received $860,000 in funding to move a bead-based genetic sequencing drug discovery technology closer to commercialization, Wake Forest said today.
Genome-wide association studies have put forward a vast number of SNPs associated with disease. Once you have those SNPs, the search is on for the causal variant.
Thermo Fisher Scientific, North Carolina Biotechnology Center, Life Technologies, Cenix BioScience, AstraZeneca, MultiCell Technologies, Maxim Biotech, CyBio, Axxam, PerkinElmer, Sangmyung University
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.